Radiation Therapy of Glomus Jugulare Tumors

Silverstone, Sidney M.

doi:10.1001/archotol.1973.00780010047012

Cited by 44 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment for paragangliomas is accomplished by surgery, radiation therapy (RT), or stereotactic radiosurgery (SRS). The possibility of cure with any of these 3 options is excellent in appropriately selected patients . Treatment depends on several factors, including the location and extent of the tumor, patient age and health, the anticipated morbidity of the treatment alternatives, and preferences of the patient and physician.…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy for benign head and neck paragangliomas: A 45‐year experience

Gilbo

Morris

Amdur

et al. 2014

Cancer

110

111

View full text Add to dashboard Cite

BACKGROUND: Paragangliomas of the head and neck are rare, slow-growing, generally benign tumors of neuroendocrine cells associated with the peripheral nervous system that commonly involve the carotid body, jugular bulb, vagal ganglia, and temporal bone. Treatment options include surgery, radiotherapy (RT), stereotactic radiosurgery (SRS), and observation. This article briefly reviews our 45-year institutional experience treating this neoplasm with RT. METHODS: From January 1968 through March 2011, 131 patients with 156 benign paragangliomas of the temporal bone, carotid body, jugular bulb, or glomus vagale were treated with RT at a median dose of 45 Gy in 25 fractions. The mean and median follow-up times were 11.5 years and 8.7 years, respectively. RESULTS: Five tumors (3.2%) recurred locally after RT, all within 10 years of treatment. The overall local control rates at 5 and 10 years were 99% and 96%, respectively. The cause-specific survival rates at 5 and 10 years were 98% and 97%, respectively. The distant-metastasis free survival rates at 5 and 10 years were 99% and 99%, respectively. The overall survival rates at 5 and 10 years were 91% and 72%, respectively. There were no severe complications. CONCLUSION: RT for benign head and neck paragangliomas is a safe and efficacious treatment associated with minimal morbidity. Surgery is reserved for patients in good health whose risk of associated morbidity is low. SRS may be suitable for patients with skull base tumors <3 cm where RT is logistically unsuitable. Observation is a reasonable option for asymptomatic patients with a limited life expectancy. Cancer 2014;120:3738-43.

show abstract

Section: Introductionmentioning

confidence: 99%

Radiotherapy for benign head and neck paragangliomas: A 45‐year experience

Gilbo

Morris

Amdur

et al. 2014

Cancer

110

111

View full text Add to dashboard Cite

show abstract

“…Glomus tumors (GT) of the temporal bone were first described in 1945 by Rosenwasser (1). These relatively rare tumors are primarily treated with microsurgery, stereotactic radiosurgery (SRS), or combined therapy (2,3). For glomus tympanicum tumors, surgery is often the preferred management method as these tumors are smaller and surgical excision generally offers complete relief.…”

mentioning

confidence: 99%

Radiosurgery of Glomus Tumors of Temporal Bone: a Meta-analysis

Sahyouni

Mahboubi

Moshtaghi

et al. 2018

Otology &Amp; Neurotology

View full text Add to dashboard Cite

Gamma Knife was the most commonly implemented radiosurgery modality and was used in eight studies. The mean marginal dose varied between 13.2 and 20 Gy. The pooled tumor control rate was 95.4% (95% CI: 93.6-97.2%) over a median follow-up duration ranging between 27.4 and 148 months. Clinical data on outcomes of SRS for the treatment of GTs are sparse and primarily limited to single institutional analyses, with considerable variation in tumor volume and follow-up duration. This meta-analysis provides an in-depth analysis of the available data in the literature and reviews the reported outcomes. Future studies on SRS for GT should include data on tumor growth before radiation as well as follow-up periods sufficiently long to identify true tumor control.

show abstract

“…In one study, 26 fibrosis was observed between sustentacular cells and the perivascular network in irradiated patients. There was control of tumor growth despite the lack of noticeable effect on principal cells.…”

Section: Discussionmentioning

confidence: 98%

“…There was control of tumor growth despite the lack of noticeable effect on principal cells. 26 In patients over 60 years old and at high risk in relation to anesthesia, this may be the treatment of choice. Such a choice is based exclusively on clinical experience and can be justified by the insidious behavior of the disease.…”

Section: Discussionmentioning

confidence: 99%

Paragangliomas of the head and neck: clinical, morphological and immunohistochemical aspects

et al. 2001

View full text Add to dashboard Cite

CONTEXT: Protein marker positivity can assist in the definition of the therapeutic approach towards head and neck paragangliomas. The establishment of the therapeutic approach should incorporate the results of such an investigation. OBJECTIVE:To establish criteria for benignancy and malignancy of vagal and jugular-tympanic paragangliomas, via the study of the relationships of sex, age, tumor size, duration of complaints, site, family history, presence of metastases, treatment, histological architecture and cell type with the immunohistochemical reactions to S100 protein, chromogranin and AgKi67. DESIGN:A retrospective study of histological and clinical records. SETTING:The Heliópolis and Oswaldo Cruz tertiary general hospitals, São Paulo. SAMPLE: 8 cases of head and neck paragangliomas. MAIN MEASUREMENTS:Determination of degree of positivity to paragangliomas via immunohistochemical reactions.RESULTS: 1). The protein markers for the principal cells (AgKi67 and chromogranin) were sensitive in 100% of the tumors when used together. 2). S100 protein was well identified in the cytoplasm and nucleus of sustentacular cells and underwent reduction in the neoplasias. CONCLUSIONS:Chromogranin was proven to be a generic marker for neuroendocrine tumors; S100 protein was positive in all 8 cases and the AgKi67 had low positivity in all cases.

show abstract

Radiation Therapy of Glomus Jugulare Tumors

Cited by 44 publications

References 36 publications

Radiotherapy for benign head and neck paragangliomas: A 45‐year experience

Radiotherapy for benign head and neck paragangliomas: A 45‐year experience

Radiosurgery of Glomus Tumors of Temporal Bone: a Meta-analysis

Paragangliomas of the head and neck: clinical, morphological and immunohistochemical aspects

Contact Info

Product

Resources

About